Safer Use of Metformin for Chronic Kidney Disease (CKD) and/or Diabetic Kidney Disease (DKD) with Beneficial Efficacy

Diabetes has been a prevalent disease worldwide, and metformin has been used widely as an oral hypoglycemic agent (OHA) for type 2 diabetes mellitus (T2DM). Its benefits include low cost, weight neutrality, general effect and positive efficacy for cardiovascular system. American Diabetes Association (ADA) has proposed diabetic guidelines-2020 and evaluated metformin as predominant agent. They include i) the preferred initial pharmacologic agent for T2DM, ii) once starting of metformin, it should be continued as long as tolerated without contraindication. Furthermore, recent studies showed safer effect for impaired renal function. We cannot exclude such results and will contribute the prevention of atherosclerotic cardiovascular disease (ASCVD).

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license(https://creativecommons.org/licenses/by/4.0/)